Filtered By:
Specialty: Cardiology
Nutrition: Sodium

This page shows you your search results in order of date.

Order by Relevance | Date

Total 159 results found since Jan 2013.

Sodium-Glucose Cotransporter-2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta-Analysis of Randomized Trials and Systematic Review
Conclusions SGLT2 inhibitors significantly reduced atherosclerotic MACEs in subjects having both chronic kidney disease and type 2 diabetes without established ASCVD.PMID:37581396 | DOI:10.1161/JAHA.123.030578
Source: Atherosclerosis - August 15, 2023 Category: Cardiology Authors: Hammad Rahman Safi U Khan Ahmad N Lone Priyanka Ghosh Mahathi Kunduru Saurabh Sharma Sudhakar Sattur Edo Kaluski Source Type: research

Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong
ConclusionsBased on real-world data of type 2 diabetic patients in Hong Kong, SGLT2I use was associated with lower risk of incident AF, stroke/transient ischemic attack, and cardiovascular and all-cause mortality outcomes compared to DPP4I use.
Source: Cardiovascular Drugs and Therapy - May 29, 2023 Category: Cardiology Source Type: research

Effectiveness of butylphthalide on cerebral autoregulation in ischemic stroke patients with large artery atherosclerosis (EBCAS study): A randomized, controlled, multicenter trial
J Cereb Blood Flow Metab. 2023 Apr 6:271678X231168507. doi: 10.1177/0271678X231168507. Online ahead of print.ABSTRACTFinding appropriate drugs to improve cerebral autoregulation (CA) in patients with acute ischemic stroke (AIS) is necessary to improve prognosis. We aimed to investigate the effect of butylphthalide on CA in patients with AIS. In this randomized controlled trial, 99 patients were 2:1 randomized to butylphthalide or placebo group. The butylphthalide group received intravenous infusion with a preconfigured butylphthalide-sodium chloride solution for 14 days and an oral butylphthalide capsule for additional 76 ...
Source: Atherosclerosis - April 6, 2023 Category: Cardiology Authors: Zhen-Ni Guo Bing-Hong Yue Lei Fan Jie Liu Yuanyuan Zhu Yuanqi Zhao Jingxin Zhong Zhan Lou Xing-Liang Liu Reziya Abuduxukuer Peng Zhang Yang Qu Ziduo Shen Baoyang Shi Ke-Jia Zhang Jia Liu Junlei Chang Hang Jin Xin Sun Yi Yang Source Type: research

Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials
Patients with type 2 diabetes are at increased risk for cardiovascular diseases. Sodium-glucose transport 2 inhibitors (SGLT2i) have been shown to enhance cardiovascular health since their debut as a second-li...
Source: Cardiovascular Diabetology - March 13, 2023 Category: Cardiology Authors: Pei-Chien Tsai, Wei-Jung Chuang, Albert Min-Shan Ko, Jui-Shuan Chen, Cheng-Hsun Chiu, Chun-Han Chen and Yung-Hsin Yeh Tags: Research Source Type: research

Long ‐term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non‐cardiac mortality
ConclusionsIn patients with acute decompensated HFpEF, over 5  years of follow-up, nearly of patients died, half from CV and the other half from non-CV causes. CAD and tricuspid regurgitation were associated with CV death. Stroke, kidney disease, lower BMI, and lower sodium were associated with non-CV death. Anaemia and higher age were associated with both ou tcomes.
Source: ESC Heart Failure - March 11, 2023 Category: Cardiology Authors: Angiza Shahim, Marion Hourqueig, Lars H. Lund, Gianluigi Savarese, Emmanuel Oger, Ashwin Venkateshvaran, Lina Benson, Jean ‐Claude Daubert, Cecilia Linde, Erwan Donal, Camilla Hage Tags: Original Article Source Type: research

Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes
Cardiol Res. 2023 Feb;14(1):12-21. doi: 10.14740/cr1459. Epub 2023 Feb 25.ABSTRACTBeyond improving hemoglobin A1c (HbA1c) in adults with type 2 diabetes, glucagon-like peptide 1 receptor agonists (GLP-1RA) have been approved for reducing risk of major adverse cardiovascular events (MACE) with established cardiovascular disease (CVD) or multiple CV risk factors. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) also reduced the risk for the primary composite CV outcome in patients with type 2 diabetes at high risk for CV events. In the American Diabetes Association (ADA) and European Association of Study in Diabetes (EASD)...
Source: Atherosclerosis - March 10, 2023 Category: Cardiology Authors: Hidekatsu Yanai Hiroki Adachi Mariko Hakoshima Hisayuki Katsuyama Source Type: research

Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong
There are limited data on head-to-head comparative risk of stroke between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA). We compared risk of stroke ...
Source: Cardiovascular Diabetology - February 24, 2023 Category: Cardiology Authors: David Tak Wai Lui, Eric Ho Man Tang, Tingting Wu, Ivan Chi Ho Au, Chi Ho Lee, Yu Cho Woo, Kathryn Choon Beng Tan and Carlos King Ho Wong Tags: Research Source Type: research

Non-calcified active atherosclerosis plaque detection with 18F-NaF and 18F-FDG PET/CT dynamic imaging
This study was aimed to assess the behavior of 18F-sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) uptake in the aorta and iliac arteries as a function of plaque density on CT images. We report metabolically active artery plaques associated to inflammation in the absence of calcification. 18 elderly volunteers were recruited and imaged with computed tomography (CT) and positron emission tomography (PET) with 18F-NaF and 18F-FDG. A total of 1338 arterial segments were analyzed, 766 were non-calcified and 572 had calcifications. For both 18F-NaF and 18F-FDG, the mean SUV values were found statistically signifi...
Source: Atherosclerosis - January 30, 2023 Category: Cardiology Authors: Abdelillah Douhi Mamdouh S Al-Enezi Nousra Berrahmoune Abdelouahed Khalil Tamas Fulop Michel Nguyen Eric Turcotte Étienne Croteau M'hamed Bentourkia Source Type: research

The uptake pattern of 18F-sodium fluoride radioligand in brain tissue after cerebral infarction
In this study, we measured the maximum and mean standardized uptake value (SUVmax and SUVmean) of NaF uptake level in the cerebral infarct region between lesions with and without diffusion weighted image (DWI) positivity, indicating acute ischemic cell death. Correlation analysis was performed between NaF uptake levels and imaging and clinical variables, including neurological severity. The NaF uptake levels were significantly higher in DWI positive lesions than in negative lesions (SUVmax: 2.0 [0.60-4.2] versus 0.20 [0.10-0.40], p = 0.021 by Mann-Whitney U test). The intensity of NaF uptake (SUVmax) was significantly corr...
Source: Atherosclerosis - December 29, 2022 Category: Cardiology Authors: Jeong-Min Kim Reeree Lee Hae-Bong Jeong Kwang-Yeol Park Ju Won Seok Source Type: research

Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials
ConclusionsSodium-glucose cotransporter inhibitors  significantly reduced major adverse cardiovascular events, including hospitalization and all-cause mortality in patients with or without established atherosclerotic cardiovascular disease. We observed a beneficial trend in patients with heart failure with preserved ejection fraction, and no benefi ts in patients with stroke or myocardial infarction.
Source: American Journal of Cardiovascular Drugs - December 27, 2022 Category: Cardiology Source Type: research

Why Are Cardiologists Not Prescribing the New Diabetes Medications?
Randomized clinical trials and guidelines from multiple societies have established significant cardiovascular (CV) outcome benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D). Among patients with T2D, those with known CV disease and those at high risk who are receiving metformin have lower risks of death, myocardial infarction, and stroke if they are treated with GLP-1RAs, and those treated with SGLT2is have reduced risks of hospital admission for heart failure, CV mortality, and all-cause mortality.
Source: The American Journal of Cardiology - December 14, 2022 Category: Cardiology Authors: Lloyd W. Klein Source Type: research

Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes
Abstract  Purpose of ReviewThis forward-looking review summarizes existing evidence from cardiovascular outcome trials on cardiometabolic risk-reduction in type 2 diabetes (T2DM) management, with attention to updating and personalizing recommendations from recent diabetes practice guidelines issued by cardiology societies.Recent FindingsT2DM management has shifted towards cardiometabolic outcome improvement rather than purely glycemic control. According to large clinical trials, sodium-glucose cotransporter-2 inhibitors showed robust results in reducing heart failure (HF) hospitalization and chronic kidney disease (CKD) p...
Source: Current Atherosclerosis Reports - November 24, 2022 Category: Cardiology Source Type: research

Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu
J Clin Med. 2022 Nov 4;11(21):6544. doi: 10.3390/jcm11216544.ABSTRACTChronic hyperglycemia induces pathophysiologic pathways with negative effects on the metabolism of most substrates as well as lipids and lipoproteins, and thereby induces dyslipidemia. Thus, the diabetic milieu is commonly accompanied by different levels of atherogenic dyslipidemia, which is per se a major risk factor for subsequent complications such as atherosclerosis, coronary heart disease, acute myocardial infarction, ischemic stroke, and nephropathy. Therefore, readjusting lipid metabolism in the diabetic milieu is a major goal for preventing dyslip...
Source: Atherosclerosis - November 11, 2022 Category: Cardiology Authors: Habib Yaribeygi Mina Maleki Željko Reiner Tannaz Jamialahmadi Amirhossein Sahebkar Source Type: research